Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.46 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.46 |
| ▸ | MARK3 | P27448 | 3/20 | 0.46 |
| ▸ | FLT4 | P35916 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 3/20 | 0.46 |
| ▸ | CLK2 | P49760 | 3/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | MAP4K5 | Q9Y4K4 | 3/20 | 0.46 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | PRKCG | P05129 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607698 | 0.84 | MAPK1 (0.42) | ROCK1ROCK2AKT3MAPK1MAP4K4 | |
| SCHEMBL3602220 | 0.81 | AKT3 (0.61) | ROCK1ROCK2AKT3MAPK1MAP4K4 | |
| SCHEMBL3608525 | 0.76 | ROCK1 (0.79) | ROCK1ROCK2AKT3MAPK1MAP4K4 | |
| SCHEMBL3602313 | 0.75 | PRKG1 (0.64) | ROCK1ROCK2AKT3MAPK1MAP4K4 | |
| SCHEMBL27819463 | 0.71 | TNIK (0.50) | ROCK1ROCK2AKT3MAPK1MAP4K4 | |
| SCHEMBL3600660 | 0.69 | ROCK1 (0.50) | ROCK1ROCK2MAP4K4FGFR1MARK3 | |
| SCHEMBL3609665 | 0.68 | CD274 (0.60) | ROCK1MAP4K4FGFR1MARK3FLT4 | |
| SCHEMBL13502654 | 0.67 | CDK8 (0.45) | ROCK1ROCK2MAP4K4MARK3FLT4 | |
| SCHEMBL3603815 | 0.67 | TNIK (0.49) | ROCK1ROCK2MAP4K4FGFR1MARK3 | |
| SCHEMBL3596684 | 0.66 | AURKB (0.56) | ROCK1ROCK2AKT3MAPK1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807688-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7459459-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-06-08 | — | — | US | disclosed |
| US-7034153-B2 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| EP-1354884-A1 | TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | NR3C1, CRHR2, CRHR1 | ROCK1 3972/4885ROCK2 3311/4885AKT3 232/4885 |
| US-20100035919-A1 | COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES | ROCK1, ROCK2, RHOA | ROCK1 1/4885ROCK2 2/4885AKT3 24/4885 |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | NR3C1, CRHR2, CRHR1 | ROCK1 3972/4885ROCK2 3311/4885AKT3 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.